Natural Matrix Product Assessment for Physiological Mode Validation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for assessing the therapeutic or beneficial effects of products comprising natural matrices, which operate through complex network interactions rather than traditional pharmacological mechanisms, leading to challenges in regulatory compliance and validation.
Innovation Solution
A method involving cell-based assays to evaluate the regulation of a network of biological activities and functional resilience across different batches of natural matrix products, determining if they modify a pathological or altered physiological state through a physiological mechanism of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional pharmacological assessment methods are used for natural matrix products, then the assessment process is simple and familiar, but the methods are inadequate for capturing complex network interactions and physiological mechanisms of action
Solution Approach 1:
The patent segments the assessment into multiple distinct components: in vitro cell-based assays, in vivo animal studies, and computational network analysis. Each component evaluates specific aspects of the product's interaction with biological systems, allowing comprehensive assessment of complex network interactions while maintaining manageable complexity through modular evaluation
Solution Approach 2:
The patent develops a multi-functional assessment framework that can evaluate both traditional pharmacological effects and novel physiological mechanisms of action. The same methodology can be applied to different natural matrix products and various types of biological interactions, providing a universal tool for assessing diverse therapeutic products with different mechanisms
2Manufacturing precision
If batch-to-batch compositional variability is reduced to ensure consistency, then manufacturing precision improves, but the natural variability inherent in natural matrices is lost
Solution Approach 1:
The patent transitions from static compositional specifications to dynamic functional assessment. Instead of requiring fixed compositional parameters, the methodology evaluates the dynamic biological responses and network interactions that result from the natural matrix, allowing compositional variability while maintaining functional consistency through physiological mechanism validation
Solution Approach 2:
The patent changes the assessment parameters from chemical composition metrics to biological activity and network interaction metrics. This parameter transformation allows natural matrices to maintain their inherent compositional variability while ensuring therapeutic consistency through evaluation of functional outcomes and physiological mechanisms rather than fixed chemical specifications
3Reliability
If comprehensive network interaction analysis is performed to validate physiological mechanisms, then therapeutic validation accuracy improves, but the time and resources required increase significantly
Solution Approach 1:
The patent employs preliminary in vitro cell-based assays to screen and characterize network interactions before proceeding to more time-consuming in vivo studies. This preliminary assessment identifies key interaction patterns and reduces the scope of subsequent animal studies, maintaining validation reliability while reducing overall assessment time through staged evaluation
Solution Approach 2:
The patent uses computational models and in vitro systems as simplified copies of complex in vivo networks. These model systems replicate key network interactions and physiological mechanisms at reduced complexity, allowing comprehensive validation of therapeutic mechanisms without requiring exhaustive animal or clinical studies for every aspect of network analysis
Data Source
AI summary
The present invention relates to new methods enabling the evolution of the medical arts passing from the use of artificial substances that are chemically or biologically defined to self-assembling natural entities, obtained from natural raw materials with industrial processes that preserve the endogenous properties thereof, thereby preserving their capability to interact with the networks of the living kingdom (including humans); wherein said natural entities cannot be defined with the classical quali-quantitative composition schemes. The invention therefore provides new methods for determining when a therapeutic or beneficial product exerts its therapeutic or beneficial effect through a physiological mode of action. This method provides a necessary tool for the skilled person to assess the mechanism of action of a therapeutic or beneficial product which, with the new developments in the regulatory framework for medical devices and food supplements has become a relevant feature to assess and for which no methods are available in the art.